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Genetic factors involved in the susceptibility to drug addiction still remain largely unknown. MiRNAs 
seem to play key roles in the drug-induced plasticity of the brain that likely drives the emergence of 
addiction. In this work we explored the role of miRNAs in drug addiction. With this aim, we selected 62 
SNPs located in the 3’UTR of target genes that are predicted to alter the binding of miRNA molecules 
and performed a case-control association study in a Spanish sample of 735 cases (mainly cocaine-
dependent subjects with multiple drug dependencies) and 739 controls. We found an association 
between rs1047383 in the PLCB1 gene and drug dependence that was replicated in an independent 
sample (663 cases and 667 controls). Then we selected 9 miRNAs predicted to bind the rs1047383 
region, but none of them showed any effect on PLCB1 expression. We also assessed two miRNAs 
binding a region that contains a SNP in linkage disequilibrium with rs1047383, but although one of 
them, hsa-miR-582, was found to downregulate PLCB1, no differences were observed between alleles. 
Finally, we explored the possibility that PLCB1 expression is altered by cocaine and we observed 
a significant upregulation of the gene in the nucleus accumbens of cocaine abusers and in human 
dopaminergic-like neurons after cocaine treatment. Our results, together with previous studies, suggest 
that PLCB1 participates in the susceptibility to drug dependence.
Drug dependence is one of the major health problems worldwide. In Europe, about 25% of adults are estimated to 
have tried illicit drugs at some point in their lives1. Usually drug consumers use more than one drug at the same 
time: for example, within the group of European individuals who consumed a psychoactive substance in the last 
12 months, 33% had consumed two different substances and 10% had used three2. This high prevalence of poly-
drug abuse is due to common and drug-specific genetic and environmental factors3–5. It is well known that addic-
tions are moderately to highly heritable (from 0.39 in the case of hallucinogens to 0.72 for cocaine), although the 
specific genetic risk factors involved in its predisposition remain largely unknown6–9. Transcriptomic studies in 
animal and cellular models, as well as human studies in postmortem brain samples from addicted individuals, 
have revealed that both acute and chronic drug exposure produce epigenetic adaptations and changes in gene 
expression10. Furthermore, recent studies have shown that some genes whose expression is altered by cocaine also 
contribute to cocaine dependence susceptibility11, 12.
MicroRNAs (miRNAs) are small regulatory noncoding RNA molecules (about 18–25 nucleotides in length) 
that control gene expression through direct binding to 3′untranslated regions (3′UTRs) of target mRNAs causing 
translational repression or mRNA degradation. One single miRNA can target and regulate hundreds of mRNAs 
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and, conversely, one mRNA can be regulated by several miRNAs. This is a complex and dynamic system that 
allows the cells to fine-tune gene expression13–15.
MiRNAs are very abundant in the central nervous system and play important roles in neuronal development, 
differentiation and survival16, 17. Many studies have shown their contribution to several psychiatric disorders 
such as schizophrenia, bipolar disorder, autism or drug dependence18–21. In human prefrontal cortex of alcoholic 
patients 35 miRNA were found up-regulated as compared to controls22. Animal model studies have demonstrated 
that drugs of abuse induce robust alterations in the expression of a wide range of miRNAs. Cocaine administra-
tion in rats alters miR-124, miR-181 and let-7 in mesolimbic dopaminergic system23, 24 and miR-212 in dorsal 
striatum25, 26. On the other hand, alcohol regulates miR-9 increasing alcohol tolerance27. Also, miRNAs have been 
shown to play an important role in different processes related to addiction such as reward, synaptic plasticity, 
learning, memory, withdrawal and relapse28.
Some studies suggest that single nucleotide polymorphisms (SNPs) located in miRNAs or in their target sites 
can alter the miRNA-mediated regulation of gene expression that underlies disease and non-pathological pheno-
types29–31. A recent study generated a transcriptome-wide map of the miRNA binding sites in human brain. Based 
on the interaction between argonaute 2 protein (AGO2) and miRNAs, they identify target regions in mRNAs. 
These regions contain 916 common SNPs that could potentially alter miRNA:mRNA binding32.
In this study, we aimed at examining the contribution to drug dependence susceptibility of SNPs that alter the 
binding of miRNAs to their target mRNAs. For that purpose we selected SNPs located in the 3’UTR identified in 
the study mentioned above and performed a case-control association study in drug addiction in a discovery and 
a replication samples from Spain. The identified variants were subjected to functional testing. Finally, we assessed 
the impact of cocaine on the expression of those genes where the associated SNPs are located.
Material and Methods
Association study. Subjects. Patients were recruited and evaluated at the Addiction and Dual Diagnosis 
Unit of the Psychiatry Department of the Hospital Universitari Vall d’Hebron (Barcelona, Spain) according 
to DSM-IV-TR criteria (Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text revision). The 
Structured Clinical Interview (SCID)33 was administered and volunteers with DSM-IV lifetime diagnosis for sub-
stance dependence were included in the study. About 73.5% of our patient sample consists of cocaine-dependent 
patients, most of which are dependent to other drugs of abuse. Controls were recruited at the Blood and Tissues 
Bank of Barcelona, and both patients and controls were Spanish and Caucasian, with the two last names (one 
from each parent) of Spanish origin. Other ethnicities such as Moroccan, Gypsies or South American individu-
als, among others, were discarded. Patients and controls were divided randomly into a discovery sample, which 
consisted of 735 patients and 739 controls, and a replication sample of 663 patients and 667 controls (Table 1 and 
Fig. 1). Population stratification was previously discarded in our sample34. The study was approved by the ethics 
committee of our institution, the Institutional Review Board of the University of Barcelona (IRB00003099), and 
informed consent was obtained from all participants, in accordance with the Helsinki Declaration. All experi-
ments were performed in accordance with relevant guidelines and regulations.
DNA isolation and quantification. Genomic DNA samples were obtained from peripheral blood lymphocytes 
using the salting-out method35 and were quantified using Nanodrop ND-1000 Spectrophotometer (Nanodrop 
Technologies, Thermo Fisher Scientific Inc., Wilmington, DE, USA).
SNP selection and genotyping. We selected SNPs in target genes that might alter the binding of regulator miRNAs 
using a previously described list of 916 SNPs located in AGO2 binding sites32. From this list we selected SNPs 
within the 3′UTR of genes and with a minimum allele frequency (MAF) of 0.15 in CEU individuals from HapMap 
project (www.hapmap.org; release 23). A total of 62 SNPs were selected under these criteria and genotyped in 
the discovery sample. We considered a maximum percentage of 5% of missing genotypes, and the SNPs finally 
evaluated had an average call rate of 99.6%. Nominally significant associated SNPs were subsequently assessed in 
a replication sample. Genotyping of both discovery and replication samples was performed by KASP technology 
(LGC, Teddington, Middlesex, UK).
Statistical analyses. The minimal statistical power for discovery (23–93%) and replication samples (18–81%) 
were calculated post hoc using the software Power Calculator for Genetic Studies (http://sph.umich.edu/csg/
abecasis/CaTS/), under the multiplicative model (equivalent to log-additive) and assuming an odds ratio (OR) 
between 1.1 and 1.3, a significance threshold of 0.05, the lowest MAF value in our study (0.119), and a prevalence 
for substance dependence of 0.02636. The R library SNPassoc37 was used to assess Hardy-Weinberg equilibrium 
Gender N (%)
Discovery sample Replication sample
Drug dependence N = 735 Control N = 739 Drug dependence N = 663 Control N = 667
Male 574 (78.1) 577 (78.1) 507 (76.5) 510 (76.5)
Female 161 (21.9) 162 (21.9) 156 (23.5) 157 (23.5)
Age (mean and SD)
37.3 ± 9.6 55.4 ± 15.9 37.3 ± 9.9 55.8 ± 16.3
Table 1. Descriptive characteristics of the Spanish Caucasian individuals with drug dependence and controls 
used in the case-control association study. SD: Standard deviation.
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(HWE, threshold set at P < 0.01) and to compare genotypic frequencies between cases and controls for each 
marker considering the log-additive model and a significance threshold of 0.05. As age differed significantly 
between cases and controls, we considered it as a covariate in all tests. All the p-values shown in the different asso-
ciation analyses are the ones adjusted for age, except in Table 2 and Supplementary Tables where both p-values 
are shown. The Bonferroni correction threshold for multiple testing was set at P < 8.5e-04 (0.05/59 SNPs) in the 
discovery sample, and at P < 7.2e-03 (0.05/7 SNPs) in the replication sample and in the pooled analysis.
Evaluation of functional effect of associated variants. Linkage disequilibrium analysis. Genotye 
data for the PLCB1 gene plus 10 kb flanking sequences upstream and downstream were available for 554 indi-
viduals from our control sample38. The analysis of linkage disequilibrium (LD) was performed using Haploview 
software39 setting a maximum r2 threshold at 0.85.
Functional evaluation of SNPs effect on microRNA regulation. We assessed the possible functional effect 
of rs1047383 and two other variants found in LD with it (rs708910 and rs1047381), all located in the 3’UTR 
of the PLCB1 gene. To do that, we used a luciferase reporter system to test the possible impact of these SNPs 
on the regulation of gene expression mediated by miRNAs, as previously described12. The prediction tools 
FuncPred, mirWalk, mirSNP, mrSNP, mirdSNP, miRNASNP and RNAhybrid were used to select miRNAs which 
binding sites in PLCB1 is potentially affected by these SNPs. We chose the best predictions for each SNP: for 
rs1047383, hsa-miR-124-1, hsa-miR-139, hsa-miR-140, hsa-miR-144, hsa-miR-377, hsa-miR-506, has-miR-548h, 
hsa-miR-1324 and hsa-mir-3148; and for rs708910, hsa-miR-582 and hsa-miR-140. All miRNAs were cloned 
into a pCMV-MIR vector (OriGene, Rockville, MD, USA) and expression was confirmed after transfection into 
HeLa or HEK293 cells by qRT-PCR using the miScript PCR System (Qiagen, Hilden, Germany). Two regions 
from the 3’UTR of the PLCB1 gene were cloned in the pmirGLO Dual-Luciferase miRNA Target Expression 
Vector (Promega, Madison, WI, USA): one fragment of the 3’UTR of the PLCB1 gene containing SNP rs1047383 
(hg19/chr20:8,864,935–8,865,116; 182 bp) and another one containing SNPs rs708910 and rs1047381 (hg19/
chr20:8,864,108–8,864,373; 267 bp). All the constructs were used to test the effect of the selected miRNAs in 
HeLa or in HEK293 cells. Luciferase expression was assessed using the Dual-luciferase Reporter Assay System 
(Promega). As our data did not follow a normal distribution (tested using Shapiro-Wilk test), differences between 
Figure 1. Distribution of the four main dependencies (cocaine, cannabis, alcohol and opiates) in the sample of 
patients included in the case-control association study, depicted in Venn diagrams. Other dependencies with a 
frequency lower than 10% are not displayed. (A) Discovery sample. (B) Replication sample.
Marker Locus
Discovery (735 cases–739 controls) Replication (663 cases–667 controls)
Pooled analysis (1393 cases–1406 
controls)
Alleles p-value1
Adj. 
p-value2 OR [95% CI]2 Alleles p-value1
Adj. 
p-value2 OR [95% CI]2 p-value1
Adj. 
p-value2 OR [95% CI]2
rs6840 SCD5 C/T 0.011 0.025 1.24 [1.03–1.50] — — — — — —
rs1285 IDI1 C/T 0.029 — C/T 0.010 0.034 1.32 [1.02–1.71] — — —
rs1872353 FBXO45 C/T 0.044 — — — — — — —
rs6855973 GRIA2 A/T 0.014 — — — — — — —
rs1047383 PLCB1 C/T 0.039 9.6e-03 1.27 [1.06–1.53] C/T 3.8e-03 1.6e-03 1.37 [1.13–1.67] 4.8e-04 3.7e-04 1.29 [1.12–1.49]
rs1057377 SPOCK3 A/G 0.026 0.033 1.23 [1.02–1.49]* — — — — — —
rs2597775 QDPR C/T 0.043 — — — — — — —
Table 2. SNPs located in miRNA binding sites associated with drug dependence. 1Log-additive model;2Ajusted by 
age; Risk allele underlined.*When OR <1 the inverted score is shown; SNP, Single Nucleotide Polymorphism.
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the two conditions were evaluated with the nonparametric Mann-Whitney U-test using the SPSS statistics soft-
ware version 22.0 (IBM, Armonk, NY, USA), and P < 0.05 was considered significant.
Effect of cocaine on PLCB1 expression. To assess the possible impact of cocaine on PLCB1 expression 
we used data available from previous studies. Data from nucleus accumbens samples of human cocaine abusers 
(10 cases and 10 controls matched by age, race, sex and brain pH) were kindly provided by the authors40. When 
comparing differences between the expression levels of PLCB1 between cases and controls, we considered the 
ratio between each case with its matched control. Normality of ratio was confirmed by using Shapiro-Wilk test 
(P = 0.91). Thus, the null hypothesis that the ratio is one, was tested with the parametric Student’s t test, using 
the SPSS statistics software version 22.0 and considering P < 0.05 as significant. Furthermore, we also used RNA 
samples obtained in a previous study from our group on the effect of cocaine on gene expression12. In this study 
we generated a human dopaminergic neuron-like model (differentiated SH-SY5Y cells) and RNA samples were 
obtained at different time points after an acute cocaine exposure (30 min). Samples were retrotranscribed using 
High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific). For the present study, we assessed 
PLCB1 expression by quantitative Real-Time PCR (qRT-PCR) using LightCycler® 480 SYBR Green I Master 
(Roche Life Sciences, Branford, CT, USA), and relative quantification was performed as previously described, 
using GAPDH and ACTB as reference genes12. As we only have three replicates for each condition, differences 
between conditions were evaluated with a t-student test41 using SPSS statistics software version 22.0.
Ethics statement. This study was approved by the local Ethics Committee and informed consent was 
obtained from all adult subjects, children and their parents according to the Helsinki declaration.
Results
In this study we evaluated the contribution to drug dependence predisposition of SNPs located in the 3’UTR of 
genes expressed in the brain that are predicted to alter the binding of miRNA molecules.
We performed a case-control association study in a sample of 735 drug-dependent patients and 739 
sex-matched controls from Spain. A total of 59 SNPs in 56 genes were finally evaluated (from the 62 SNPs that 
were genotyped, one showed poor genotyping and two were not in HWE). The comparison of genotype fre-
quencies between cases and controls under the log-additive model showed nominally significant differences 
before adjusting by age for seven SNPs located in the genes SCD5, IDI1, FBXO45, GRIA2, PLCB1, SPOCK3 and 
QDPR (Table 2 and Supplementary Table S1). These associated SNPs were subsequently evaluated in an inde-
pendent Spanish sample of 663 drug-dependent patients and 667 sex-matched controls and the association 
remained significant for rs1285 in the IDI1 gene (P = 0.034; OR = 1.32, CI = [1.02–1.71]) and rs1047383 in the 
PLCB1 gene (P = 1.6e-03; OR = 1.37, CI = [1.13–1.67]). In the first one the direction of the effect was not the 
same in the discovery and replication samples, but it was so for the rs1047383 association, which also survived 
the Bonferroni correction (Table 2 and Supplementary Table S2). In the pooled analysis of both the discovery 
and replication samples, only rs1047383 in the PLCB1 gene remained associated with the disorder (P = 3.7e-04; 
OR = 1.29, CI = [1.12–1.49], Table 2 and Supplementary Table S3), with a higher frequency of subjects carrying 
the C allele in the group of drug-dependent subjects (39%) as compared to controls (35%). This association 
withstood the Bonferroni correction for multiple testing. Finally, we also explored these results in the subgroup 
of cocaine-dependent patients, including patients where cocaine is one of multiple drugs of abuse or the only 
one (about 75% of our patients’ sample), and the association remained significant both in the discovery sample 
(551 cases; P = 0.03; OR = 1.25, CI = [1.02–1.53]) and in the replication sample (478 cases; P = 0.01; OR = 1.35, 
CI = [1.05–1.73]), and also in the pooled analysis (1,029 cases; P = 5.7e-03; OR = 1.26, CI = [1.07–1.48]).
We selected nine different miRNAs that potentially target the 3’UTR of PLCB1, with their binding being pre-
dicted to be affected by variation in rs1047383. No regulatory effect on PLCB1 expression was observed for any of 
the assayed miRNAs using a gene reporter system in HeLa cells. We then investigated the existence of SNPs in LD 
with rs1047383 and found two polymorphisms, rs6056229 and rs708910 (r2 = 1 and 0.88, respectively). The first 
one is located outside the PLCB1 gene and we could not find any functional prediction for it. The latter is located 
within the 3’UTR of PLCB1 and is predicted to alter a binding site for several miRNAs by the FuncPred software. 
This SNP is only 25 bp distant from another SNP, rs1047381, which is in moderate LD with the associated variant 
in our Spanish sample (r2 = 0.61). To test this, we used a construct that includes both SNPs and assessed the possi-
ble effect of the two most frequent haplotypes (rs1047381C-rs708910G and rs1047381T-rs708910A) on the regu-
lation mediated by hsa-miR-140 and hsa-miR-582. No differences were observed in HeLa cells, but in this cell line 
hsa-miR-582 could not be successfully overexpressed upon transfection. For this reason we repeated the experi-
ment in HEK293 and observed that hsa-miR-582 decreases PLCB1expression (25%, P = 3.96e-03, Supplementary 
Figure 2), but without differences between the two rs1047381-rs708910 haplotypes.
Previous studies had reported that two genes (NFAT5 and NTNG1) with altered expression under cocaine 
also bear variants that confer susceptibility to cocaine dependence as shown by association studies11, 12. Since we 
have shown that PLCB1 is involved in the vulnerability to cocaine dependence, we explored the possibility that 
its expression is altered by the action of cocaine. For that purpose we used data from a previous study using sam-
ples from nucleus accumbens of human cocaine abusers40. The sample’s mean expression levels of PLCB1 gene 
were increased by 1.19-fold (P = 0.012) when we compared each case with its matched control. Furthermore, we 
investigated the effect of cocaine on the regulation of PLCB1 in a human neuron-like dopaminergic model (dif-
ferentiated SH-SY5Y cells) using samples previously produced in our lab12. We have now performed qRT-PCR 
experiments in this model and, interestingly, a significant upregulation of PLCB1 after cocaine treatment was 
observed, showing a maximum of 1.65-fold increase (P = 5.8e-03) as compared to untreated cells (Fig. 2).
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Discussion
In this study we explored, for the first time, the possible role in drug dependence of SNPs located in the 3’UTR 
of genes potentially altering the binding of the corresponding mRNA to miRNA molecules. These SNPs were 
selected on the basis of a previous study32 which listed variants located in binding sites for the AGO2 protein, 
one of the molecules of the RNA-induced silencing complex (RISC) that interacts with both the miRNA and 
the mRNA. We found that the rs1047383 variant in the PLCB1 gene is associated with drug dependence in two 
independent samples. Then we investigated a possible effect of this SNP and rs1047381-rs708910 (in LD with 
rs1047383) on miRNA binding, with negative results for all the tested miRNAs (a total of 10 out of 35 predictions 
identified in the databases we used). The only exception was hsa-miR-582, which reduced gene expression but 
with no differences between the two rs1047381-rs708910 haploalleles. It is important to note that, although many 
prediction tools are available, the degree of overlap of the different outputs is often limited14, so ranking the pre-
dictions is not straightforward.
The PLCB1 gene encodes the Phospholipase C beta 1 protein expressed in the brain, mainly in cortex, hip-
pocampus and amygdala. It is considered a molecular mediator of synaptic plasticity and it plays an important 
role in modulating cognitive behavior and emotions42, 43. Many neurotransmitters such as dopamine, seroto-
nin and glutamate activate PLCβ1 by a G-protein-coupled receptor that signals through Gq/1144–47. Furthermore, 
PLCB1 has previously been related to other psychiatric and neurological disorders such as schizophrenia, autism 
and epilepsy48–52.
Several lines of evidence support a role for PLCB1 in drug dependence. A region of overlapping clusters of 
SNPs in the PLCB1 gene were identified in a previous study that assessed common genomic regions in two GWAS 
of illegal substance dependence and cocaine dependence53. However, in another GWAS reported by Gelernter 
et al. in 201454 none of the PLCB1 SNPs showed a suggestive association (P < 1e-05) with cocaine dependence. 
These discordant results might be explained by differences in the case-control designs, as the controls used in 
their study54 were individuals not dependent to cocaine who had taken this drug at least once in their lives and, 
in our study, the controls were individuals from the general population. Also, increased Plcb1 expression was 
Figure 2. Expression of the PLCB1 gene after treatment with cocaine. (A) Expression levels in the nucleus 
accumbens of cocaine abusers compared with their matched controls. (B) Transcription levels in human 
dopaminergic neuron-like cells (differentiated SH-SY5Y) at different time points after a 30-min exposure to 
5 μM cocaine. Significant differences compared to control cells (not exposed to cocaine) normalized to GAPDH 
are indicated. Error bars indicate s.d. *p-value < 0.05, **p-value < 0.01.
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previously described in the nucleus accumbens of mice after administration of cocaine during 7 days and also 
during withdrawal55. This is consistent with our results, in which we identified increased expression in both the 
nucleus accumbens of human cocaine abusers and in cultured dopaminergic-like human neurons treated with 
cocaine. Furthermore, a previous study of our group identified changes in the expression of PLCB1 in a mouse 
model of frustrated expected reward56.
In conclusion, although we could not prove that the SNP found associated with the phenotype alters 
miRNA-mediated regulation of gene expression, our data provide evidence for the contribution of the PLCB1 
gene to cocaine dependence, identifying an associated variant that was replicated in a second sample, as well as 
alterations in the expression of PLCB1 induced by cocaine.
Several strengths and limitations of the present study should be discussed. Strengths: i) To minimize sample 
heterogeneity, both patients and controls in the discovery and replication samples were recruited in the same 
small geographical area around Barcelona (Spain); cases and controls were Spanish, Caucasian and sex-matched; 
ii) cases were evaluated by following a unique clinical assessment; iii) the associated variant was replicated in 
a second independent sample; iv) altered expression of PLCB1 induced by cocaine was seen in human brain 
post-mortem samples and also in a human neuron-like model, with the same direction; v) previous studies are in 
agreement with our findings at PLCB1 both in the association and expression studies. Limitations: i) The disease 
phenotype was not excluded in the control samples, which may have potentially diluted positive findings in the 
association study; ii) the sample size, 1398 cases and 1406 controls, is relatively small and may have led to false 
negative results; iii) the associated variant could not be proven to have a functional effect on the binding of any 
of the tested miRNAs, although it could have an effect on other non-investigated miRNAs; iv) changes in PLCB1 
expression levels could be proven at mRNA level but we could not test the protein as samples were not available 
for this type of analysis.
In conclusion, a variant in the PLCB1 gene was found associated with drug dependence in two independent 
samples. Although the sample size is altogether relatively small, the results obtained in the discovery sample have 
been replicated. Also, the expression of PLCB1 was found to be altered by cocaine. Together with previous results, 
this study highlights PLCB1 as a gene that may contribute to drug dependence. Finally, these findings and previ-
ous results from our and other groups on NFAT5 and NTNG111, 12 suggest that genes which expression is altered 
by the effect of drugs of abuse may play an important role in the susceptibility to drug dependence.
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